Detection of serum and tissue levels of interleukin 39 in psoriasisHassan, Mohammed (Avtor) Abd El-Raheem, Talal A. (Avtor) Shake, Olfat G. (Avtor) Kamal, Hagar Ali (Avtor) Yaseen, Sara M. (Avtor) Soliman, Amira E. (Avtor) psoriasiscytokinesautoimmune diseaseIL-39ELISAIntroduction: Psoriasis is a chronic immune-mediated disorder with a genetic component that primarily affects the skin and has potential systemic involvement. Advances in understanding the interaction between the innate and adaptive immune systems have facilitated improved disease management. Methods: This study included 25 patients with psoriasis and 20 healthy controls of both sexes. All participants underwent detailed medical history-taking and dermatological examination, including assessment of the body surface area and the Psoriasis Area and Severity Index (PASI). Blood samples (3 ml) were collected from all subjects, and 4 mm lesional skin punch biopsies were obtained from psoriatic patients and healthy controls. Results: Serum and tissue levels of interleukin 39 (IL-39) were significantly elevated in psoriatic patients compared to healthy individuals. Patients with a positive family history of psoriasis showed higher serum IL-39 levels than those without such a history. In addition, psoriatic individuals with diabetes mellitus or hypertension had higher serum IL-39 levels than those without these comorbidities. A statistically significant correlation was found between disease severity and serum IL-39 concentration. Conclusions: Elevated serum and tissue IL-39 levels in psoriatic patients suggest a potential role for IL-39 in the pathogenesis of psoriasis, highlighting its possible utility as a biomarker or therapeutic target.20252026-06-09 08:38:06Neznano29905UDK: 616.5:579ISSN pri članku: 1318-4458DOI: 10.15570/actaapa.2025.13COBISS_ID: 260272387sl